|
市場調查報告書
藥品・生物科技企業之法律順應策略的成功
Successful Pharmabiotech Alliance Strategies: Driving synergies, avoiding failure and managing relationships
|
藥品・生物科技企業之法律順應策略的成功 是由出版商Business Insights在2008年09月所出版的。
這份英文市場調查報告書包含143 pages 價格從美金3835起跳。
Abstract
In recent years, alliances between pharma and biotech companies have become
common, with hundreds of relationships currently in place for drug
developments across virtually all high priority conditions. Such alliances are
of significant benefit to pharma companies who are aiming to combat the
increasing need for new product development and rapidly escalating R&D costs.
For biotechs, alliances provide crucial funding that can help to maintain and
expand R&D activities. These synergistic benefits have resulted in over 30% of
drugs in clinical trials now being a direct product of pharma-biotech
alliances. However, poor deal structure and implementation continue to
contribute to the failure of almost half of these relationships.
ĹSuccessful Pharma-Biotech Alliance Strategiesí is a new report
published by Business Insights that examines the current landscape for
pharma-biotech alliances and provides an in-depth analysis of the underlying
factors that can determine their success or failure. Recent major joint
ventures, acquisitions and licensing deals are evaluated and the latest trends
and developments affecting alliance management are assessed. This report also
performs a detailed examination of 9 case studies that profile varying
approaches to deal structuring and relationship management, in addition to
charting the current and future alliance activities of the top ten
pharmaceutical companies. Volume and value forecasts for pharma-biotech deals
to 2015 are also provided. Improve the effectiveness of your alliance
strategies with this reportĺs detailed examination of the key issues
influencing the success of relationships and a case study analysis of major
recent alliances.
Table of Contents
Executive summary
- Pharma and biotech company synergies
- Overview of pharma-biotech alliances
- Why pharma-biotech alliances fail
- Strategies to manage pharma-biotech alliances
- The future of pharma-biotech alliance management
Chapter 1 Pharma and biotech company synergies
- Summary
- Background
- The pharmaceutical industry
- The research and development process
- Resources
- Constraints and pressures
- The biotechnology industry
- The research and development process
- Resources
- Constraints and presures
- Drug development today
- More sophisticated science
- More complicated disease targets
- Rapidly escalating costs
- Declining R&D productivity
- Conclusions
Chapter 2 Overview of pharma- biotech alliances
- Summary
- Introduction
- Evolution of major alliances
- Genentech
- ImClone
- MedImmune
- Current deal trends
- Types of relationships currently undertaken
- Licensing
- Significant recent pharma-biotech licensing deals
- Joint ventures
- Significant recent pharma-biotech joint ventures
- Acquisitions
- Significant recent pharma-biotech acquisitions
- Hostile takeovers
- Offshore alliances
- Japan
- China
- India
- Canada
- Number and value of alliances
- Key therapeutic areas for pharma-biotech alliances
- Conclusions
Chapter 3 Why pharma-biotech alliances fail
- Summary
- High failure rates
- Symptoms of alliance failure
- Factors that do not affect alliance success
- Main causes of alliance failure
- Management changes
- Culture
- Project organization and expectations
- Alliance goals
- Incentives
- Roles and responsibilities
- Sharing of business processes
- Decision support infrastructure
- Project and alliance leadership
- Harmonization of information technology
- Timelines and budgets
- Alliance expectations
- Other preventable problems
- Technology failure
- The drug approval process
- Drug development success rates
- Case study: Alza and Scios
- Vulnerability by alliance type
- Licensing deals
- Joint ventures
- Acquisitions
- Conclusions
Chapter 4 Strategies to manage pharmabiotech alliances
- Summary
- Determining alliance success
- Performance measurement
- Alliance goals versus company goals
- Why effective alliance management is crucial
- Key alliance management strategies
- Deal structure 104
- Case study : Wyeth
- Case study : Novartis
- Relationship managing and monitoring
- Case study : Eli Lilly
- Case study : GlaxoSmithKline
- Exploiting synergies across alliances
- Biologics consolidation
- Case study: AstraZeneca
- Case study: Novartis
- Case study: Pfizer
- Addressing corporate culture
- Case study: WuXi PharmaTech
- Leadership continuity
- Renegotiation
- Third party services
- Conclusions
Chapter 5 The future of pharma-biotech alliance management
- Summary
- Increasing reliance on biotech by Big Pharma
- Positions of the leading pharmaceutical companies
- AstraZeneca
- Bayer
- Eli Lilly
- GlaxoSmithKline
- Johnson & Johnson
- Merck
- Novartis
- Pfizer
- Sanofi-Aventis
- Weyth
- Deal trends
- Number and value
- Therapeutic areas
- Types of relationships
- Offshore relationships
- Relationship management trends
- Conclusions
- Index
List of Figures
- Figure 1.1: U.S. NME approvals vs. R&D spend, 1980 - 2007
- Figure 1.2: U.S. R&D spend per NME approval by year, 1990 - 2007
- Figure 2.1: Comparison of key types of pharma-biotech alliances
- Figure 2.2: Volume and value of biolicensing deals, 1997 - 2007
- Figure 3.1: Compounds tested by phase of development, 2008
- Figure 3.2: Pharma-biotech alliance failure trends by alliance type
- Figure 4.1: Pharma, biotech and alliance goals
- Figure 4.2: Roles and responsibilities for alliance personnel
- Figure 4.3: Biologics consolidation vs. alliance consolidation
- Figure 5.1: Volume and value of biolicensing deals, 2005 - 2015 (est.)
List of Tables
- Table 1.1: Characteristics of pharmaceutical companies and biotechs, 2008
- Table 1.2: Pharma and biotech views of alliances, 2008
- Table 1.3: R&D expenditure within the U.S. and abroad by PhRMA members
- Table 1.4: U.S. R&D spend per NME approved, 1990 - 2007
- Table 2.5: Significant recent pharma-biotech licensing deals
- Table 2.6: Significant recent pharma-biotech licensing deals (continued)
- Table 2.7: Significant recent pharma-biotech licensing deals (continued)
- Table 2.8: Significant recent pharma-biotech licensing deals (continued)
- Table 2.9: Significant recent pharma-biotech licensing deals (continued)
- Table 2.10: Significant recent pharma-biotech acquisitions
- Table 2.11: Significant recent pharma-biotech acquisitions (continued)
- Table 2.12: Significant recent pharma-biotech acquisitions (continued)
- Table 3.13: Cultural characteristics of pharmaceutical companies and
biotechs
- Table 4.14: Selected GlaxoSmithKline biotech alliances, 2008
- Table 4.15: Capabilities of selected alliance management specialists
- Table 5.16: Current and future biotech positions of top 10 pharmaceutical
companies, 2008
|
